Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification

Background: Neurofibromatosis type 2 (NF2) is almost unique among inherited disorders in the frequency of mosaicism in the first affected generation. However, the implications of this on transmission risks have not been fully elucidated. Methods: The expanded database of 460 families with NF2 and 70...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of medical genetics Ročník 44; číslo 7; s. 424 - 428
Hlavní autori: Evans, D Gareth R, Ramsden, R T, Shenton, A, Gokhale, C, Bowers, N L, Huson, S M, Pichert, G, Wallace, A
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London BMJ Publishing Group Ltd 01.07.2007
BMJ
BMJ Publishing Group LTD
BMJ Group
Predmet:
ISSN:0022-2593, 1468-6244, 1468-6244
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background: Neurofibromatosis type 2 (NF2) is almost unique among inherited disorders in the frequency of mosaicism in the first affected generation. However, the implications of this on transmission risks have not been fully elucidated. Methods: The expanded database of 460 families with NF2 and 704 affected individuals was analysed for mosaicism and transmission risks to offspring. Results: 64 mosaic patients, with a projected mosaicism rate of 33% for sporadic classical NF2 with bilateral vestibular schwannoma at presentation and 60% for those presenting unilaterally, were identified. Offspring risks can be radically reduced on the basis of a sensitive mutation analysis of blood DNA including multiple ligation-dependent probe amplification (MLPA, which detects 15% of all mutations), but even MLPA cannot detect high levels of mosaicism. Conclusion: The chances of mosaicism in NF2 and the resultant risks of transmission of the mutation to offspring in a number of different clinical situations have been further delineated. The use of MLPA in this large NF2 series is also reported for the first time.
Bibliografia:Correspondence to:
 Professor D G R Evans
 Department of Medical Genetics, St Mary’s Hospital, Hathersage Road, Manchester M13 0JH, UK;gareth.evans@cmmc.nhs.uk
PMID:17307835
local:0440424
ark:/67375/NVC-RWDX8ZCL-B
istex:F929FDC01DAB26001DF8F88EEA9837A45DFDCF96
href:jmedgenet-44-424.pdf
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0022-2593
1468-6244
1468-6244
DOI:10.1136/jmg.2006.047753